IVR Dose 2

DEVICE2 trials

Sponsors

Daré Bioscience, Inc.

Conditions

Vasomotor SymptomsVulvovaginal Atrophy

Phase 1

Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women

CompletedNCT05367973

Daré Bioscience, Inc.Vasomotor Symptoms, Vulvovaginal Atrophy

Start: 2022-04-11End: 2023-03-23Updated: 2024-10-31

A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women

CompletedNCT05418426

Daré Bioscience, Inc.Vasomotor Symptoms, Vulvovaginal Atrophy

Start: 2020-08-18End: 2022-01-27Updated: 2024-10-15